[Drug monitoring for valproic acid with HPLC or EMIT and concomitant measurements of clinical-chemical parameters (author's transl)].
Drug monitoring for valproic acid (Convulex) was performed in 200 children with a newly developed HPLC procedure and in part with an enzyme immunoassay (EMIT). In addition the activities of the transaminases and the lipase were determined as well as platelet count, prothrombin time, thrombin time, partial thromboplastin time, fibrinogen concentration and in some cases the coagulation factors II, V and X. There is not a higher frequency for pathological laboratory findings with higher serum levels. 81 children exhibited pathological findings, however only in one case therapy had to be stopped. Recommendations when to stop therapy are given.
D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002624:Chemistry, Clinical; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008049:Lipase / Q000097:blood; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011517:Prothrombin Time; D013918:Thrombin Time; D014635:Valproic Acid / Q000097:blood*
D014635:Valproic Acid; D005340:Fibrinogen; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008049:Lipase
Kontrolle der Valproinsäure-Therapie durch Serumspiegelbestimmungen mit HPLC oder EMIT und durch gleichzeitige Bestimmung klinisch-chemischer Parameter.